Increased levels of hypoxia-inducible factor-1α are associated with Bcl-xL expression, tumor apoptosis, and clinical outcome in chondrosarcoma

Journal of Orthopaedic Research

Volumn 29, Issue 1, 2011, Pages 143-151

  Chen, Changbao ^a   Zhou, Hua ^a   Wei, Feng ^a   Jiang, Liang ^a   Liu, Xiaoguang ^a   Liu, Zhongjun ^a   Ma, Qingjun ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

apoptosis; Bcl xL; chondrosarcoma; clinical outcome; hypoxia inducible factor 1

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN BCL XL;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GENETICS; CANCER SURVIVAL; CELL HYPOXIA; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SURVIVAL RATE; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; APOPTOSIS; BCL-X PROTEIN; BONE NEOPLASMS; CELL LINE, TUMOR; CHONDROSARCOMA; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED;

EID: 78649615697     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21193     Document Type: Article

References (43)

1. Harris AL,. 2002. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
2. Shannon AM, Bouchier-Hayes DJ, Condron CM, et al. 2003. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29: 297-307.
3. Rankin EB, Giaccia AJ,. 2008. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678-685.
4. Wang GL, Jiang BH, Rue EA, et al. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514.
5. Tanimoto K, Makino Y, Pereira T, et al. 2000. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J 19: 4298-4309.
6. Ohh M, Park CW, Ivan M, et al. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423-427.
7. Hirota K, Semenza GL,. 2006. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 59: 15-26.
8. Hanahan D, Weinberg RA,. 2000. The hallmarks of cancer. Cell 100: 57-70.
9. Bruick RK,. 2000. Expression of the gene encoding the proapoptotic Nip3 protein is induced by hypoxia. Proc Natl Acad Sci USA 97: 9082-9087.
10. Sowter HM, Ratcliffe PJ, Watson P, et al. 2001. HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res 61: 6669-6673.
11. Kim M, Park SY, Pai HS, et al. 2004. Hypoxia inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by blocking Bax translocation. Cancer Res 64: 4078-4081.
12. Dong Z, Venkatachalam MA, Wang J, et al. 2001. Up-regulation of apoptosis inhibitory protein IAP-2 by hypoxia. Hif-1-independent mechanisms. J Biol Chem 276: 18702-18709.
13. Chen N, Chen X, Huang R, et al. 2009. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem 284: 10004-10012.
14. Schindl M, Schoppmann SF, Samonigg H, et al. 2002. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res 8: 1831-1837.
15. Winter SC, Shah KA, Han C, et al. 2006. The relation between hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression with anemia and outcome in surgically treated head and neck cancer. Cancer 107: 757-766.
16. Osada R, Horiuchi A, Kikuchi N, et al. 2007. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 38: 1310-1320.
17. Birner P, Schindl M, Obermair A, et al. 2000. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693-4696.
18. Adams JM, Cory S,. 1998. The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326.
19. Reed JC, Miyashita T, Takayama S, et al. 1996. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60: 23-32. (Pubitemid 26047917)
20. Kumar B, Cordell KG, Lee JS, et al. 2008. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26: 3128-3137.
21. Chen Y, Sun R, Han W, et al. 2001. Nuclear translocation of PDCD5 (TFAR19): an early signal for apoptosis? FEBS Lett 509: 191-196.
22. Bertoni F, Bacchini P, Hogendoorn PCW,. 2002. Chondrosarcoma. In:, Fletcher CDM, Unni KK, Mertens F, editors. World Health Organisation classification of tumours. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; p 247-251.
23. Evans HL, Ayala AG, Romsdahl MM,. 1977. Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading. Cancer 40: 818-831.
24. Semenza GL,. 1999. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 15: 551-578.
25. Chen C, Zhou H, Xu L, et al. 2010. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo. Apoptosis 15: 805-813.
26. Zhong H, De Marzo AM, Laughner E, et al. 1999. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835.
27. Kubo T, Sugita T, Shimose S, et al. 2008. Expression of hypoxia-inducible factor-1alpha and its relationship to tumour angiogenesis and cell proliferation in cartilage tumours. J Bone Joint Surg Br 90: 364-370.
28. Enneking WF, Spanier SS, Goodman MA,. 2003. A system for the surgical staging of musculoskeletal sarcoma 1980. Clin Orthop Relat Res 415: 4-18.
29. Gelderblom H, Hogendoorn PC, Dijkstra SD, et al. 2008. The clinical approach towards chondrosarcoma. Oncologist 13: 320-329.
30. McGough RL, Lin C, Meitner P, et al. 2002. Angiogenic cytokines in cartilage tumors. Clin Orthop Relat Res 397: 62-69.
31. Lin C, McGough R, Aswad B, et al. 2004. Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res 22: 1175-1181.
32. Liao D, Corle C, Seagroves TN, et al. 2007. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 67: 563-572.
33. Kimura S, Kitadai Y, Tanaka S, et al. 2004. Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer 40: 1904-1912.
34. Rozeman LB, Cleton-Jansen AM, Hogendoom PCW, et al. 2006. Pathology of primary malignant bone and cartilage tumours. Int Orthop 30: 437-444.
35. Terek RM,. 2006. Recent advances in the basic science of chondrosarcoma. Orthop Clin North Am 37: 9-14.
36. Chi JT, Wang Z, Nuyten DS, et al. 2006. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3: e47.
37. Weinmann M, Belka C, Guner D, et al. 2005. Array-based comparative gene expression analysis of tumor cells with increased apoptosis resistance after hypoxic selection. Oncogene 24: 5914-5922.
38. Greijer AE, van der Groep P, Kemming D, et al. 2005. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206: 291-304.
39. Dong Z, Wang J,. 2004. Hypoxia selection of death-resistant cells. A role for Bcl-X(L). J Biol Chem 279: 9215-9221.
40. Park SY, Billiar TR, Seol DW,. 2002. Hypoxia inhibition of apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biochem Biophys Res Commun 291: 150-153.
41. Amling M, Neff L, Tanaka S, et al. 1997. Bcl-2 lies downstream of parathyroid hormone-related peptide in a signaling pathway that regulates chondrocyte maturation during skeletal development. J Cell Biol 136: 205-213.
42. Bovee JV, van den Broek LJ, Cleton-Jansen AM, et al. 2000. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma. Lab Invest 80: 1925-1934.
43. Hameetman L, Kok P, Eilers PH, et al. 2005. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting. Virchows Arch 446 (4): 430-437.